Company intelligence / Profile preview

Gesynta Pharma

Ownership: Private
Development stage: Phase 2

Overview

Vipoglanstat has demonstrated a favorable safety profile and potent inhibition of mPGES‑1 in phase I and II trials. Preclinical studies showed marked reduction of endometriotic lesions and pain. A European phase II trial enrolling ~190 patients with endometriosis will evaluate efficacy and safety over four months; GS‑073 has shown strong preclinical results for inflammation/pain and will enter phase I.

Therapeutic areas: Women's HealthImmunologyRheumatology
Modalities: small molecules (mPGES‑1 inhibitors)
Industry: Biotech

Drug pipeline

2 assets

vipoglanstat

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharma partnerships disclosed; key investors include Hadean Ventures, Industrifonden, Linc AB, Innovestor Life Science Fund, Amboy Street Ventures, Foreground Capital LLC, Stephen Industries Inc Oy, Catalyze Capital.

Beyond the preview

Go deeper on Gesynta Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gesynta Pharma.

Explore the full profile